These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 32847602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, Li KHC, Tang Y, Wei Y, Tse G, Xia Y.
    Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W, Chen X, Xie X, Xu M, Xu L, Liu P, Luo B.
    J Cardiovasc Pharmacol; 2022 Mar 01; 79(3):281-288. PubMed ID: 34935705
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY, Zhang N, Chen R, Zhao JG, Yu P.
    J Diabetes Complications; 2015 Mar 01; 29(8):1295-303. PubMed ID: 26365905
    [Abstract] [Full Text] [Related]

  • 6. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
    Sfairopoulos D, Liu T, Zhang N, Tse G, Bazoukis G, Letsas K, Goudis C, Milionis H, Vrettos A, Korantzopoulos P.
    Heart Fail Rev; 2023 Jul 01; 28(4):925-936. PubMed ID: 36282460
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH.
    Cardiovasc Diabetol; 2021 May 07; 20(1):100. PubMed ID: 33962654
    [Abstract] [Full Text] [Related]

  • 9. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Xu B, Kang B, Zhou J.
    Clin Res Cardiol; 2024 Jun 07; 113(6):910-923. PubMed ID: 38353684
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RI, CREDENCE Trial Investigators*.
    Stroke; 2021 May 07; 52(5):1545-1556. PubMed ID: 33874750
    [Abstract] [Full Text] [Related]

  • 12. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study.
    Eroglu TE, Coronel R, Souverein PC.
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul 16; 10(4):289-295. PubMed ID: 38520149
    [Abstract] [Full Text] [Related]

  • 13. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis.
    Li C, Yu J, Hockham C, Perkovic V, Neuen BL, Badve SV, Houston L, Lee VYJ, Barraclough JY, Fletcher RA, Mahaffey KW, Heerspink HJL, Cannon CP, Neal B, Arnott C.
    Diabetes Obes Metab; 2022 Oct 16; 24(10):1927-1938. PubMed ID: 35589614
    [Abstract] [Full Text] [Related]

  • 14. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.
    Wang M, Zhang Y, Wang Z, Liu D, Mao S, Liang B.
    J Thorac Dis; 2022 May 16; 14(5):1620-1637. PubMed ID: 35693625
    [Abstract] [Full Text] [Related]

  • 15. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC, Chang KC, Lin SJ, Chien RN, Hung MJ, Chan YY, Kao Yang YH, Lai EC.
    Cardiovasc Diabetol; 2020 Feb 12; 19(1):17. PubMed ID: 32050968
    [Abstract] [Full Text] [Related]

  • 16. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH.
    Sci Rep; 2019 Sep 10; 9(1):13009. PubMed ID: 31506585
    [Abstract] [Full Text] [Related]

  • 17. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.
    Albulushi A, Tanoh DB, Almustafa A, Al Matrooshi N, Zolty R, Lowes B.
    Cardiovasc Diabetol; 2024 Aug 31; 23(1):324. PubMed ID: 39217337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BYQ, Yeo TC, Lee CH, Lin W, Sia CH.
    J Am Heart Assoc; 2021 Feb 31; 10(5):e019463. PubMed ID: 33625242
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.